Oruka Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $44.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that highlight Oruka Therapeutics’ promising prospects. The recent robust growth in revenue for drugs like Skyrizi and Bimzelx indicates a positive market environment for Oruka’s ORKA-001 and ORKA-002, which are expected to offer longer dosing intervals and potentially improved efficacy. The completion of dosing in the Phase 1 HV trial for ORKA-001 and the anticipated data release at EADV in September 2025 are crucial milestones, as the data is expected to confirm a superior half-life compared to existing treatments, supporting less frequent dosing and potentially enhanced efficacy.
Furthermore, the ongoing Phase 2a trial of ORKA-001 in psoriasis and the upcoming Phase 1 data for ORKA-002 suggest significant potential for these therapies in capturing market share. The company’s strong cash position, expected to fund operations through 2027, adds financial stability to its growth trajectory. The potential for ORKA-001 to offer extended off-treatment remissions and reduced injection burdens is likely to be well-received by patients and payers, further reinforcing the stock’s upside potential.
Harrison covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Oruka Therapeutics, and Protagonist Therapeutics. According to TipRanks, Harrison has an average return of 17.8% and a 48.44% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $41.00 price target.